# Taifeier biomedical (Suzhou)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/taifeier-biomedical-suzhou

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Latest round: Series B (Aug 2, 2021)
- Investors on record: 6

## About

Based in Suzhou, China, and founded in 2004.  Taifeier biomedical (Suzhou) is a pharmaceutical enterprise, committed to the research and development of small molecule drugs. Dr. Yu Chongxi, the company's founder and chief executive officer, led and completed the research and development of small molecule drugs. In August 2021, the company raised series B funding led by CAS Investment Management, followed by SND Ventures Group, Tasly Holding Group, Greatwall Fund, and Junchuan Capital. 

The company focuses on small molecule medicine, it has products in the fields of inflammatory diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, and depression.

This financing will be used to support phase III and phase II clinical trials, as well as the construction of the talent team and the upgrading of the research and development center.

## Funding rounds

- Series B, Aug 2, 2021 — CAS Investment Management, SND Ventures Group, Greatwall Fund, Tasly Holding Group, Junchuan Capital
- Series A, Mar 1, 2010 — Zheshang Venture Capital

## Investors

- Zheshang Venture Capital (https://capitalatlas.ai/funds/zheshang-venture-capital) — Series A
- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series B
- SND Ventures Group (https://capitalatlas.ai/funds/snd-ventures-group) — Series B
- Greatwall Fund (https://capitalatlas.ai/funds/greatwall-fund) — Series B
- Tasly Holding Group — Series B
- Junchuan Capital (https://capitalatlas.ai/funds/junchuan-capital) — Series B